Characterising the castration-resistant prostate cancer population: a systematic review

Area of Science:

• Oncology
• Epidemiology
• Cancer Research

Background:

• Castration-resistant prostate cancer (CRPC) is an advanced stage of prostate cancer with poor survival rates.
• Epidemiological characterization of CRPC is challenging due to inconsistent terminology, definitions, and management strategies.
• This review aims to clarify the existing epidemiological evidence for CRPC and inform future research.

Purpose of the Study:

• To systematically review the available epidemiological data on CRPC.
• To provide clarity on the prevalence, progression, characteristics, and outcomes of CRPC.
• To guide future research by identifying gaps and inconsistencies in current studies.

Main Methods:

• Systematic literature searches of PubMed and Embase databases were conducted in March 2010.
• Included observational studies focused on the epidemiology, progression, and outcomes of CRPC.
• Manual searches of bibliographies and reference lists of identified articles were performed to ensure comprehensive inclusion.

Main Results:

• Twelve articles reporting on 71,179 patients were included.
• CRPC develops in 10-20% of prostate cancer patients within approximately 5 years.
• ≥84% of CRPC patients have bone metastases at diagnosis; median survival is 9-30 months (pooled estimate: 14 months).
• Few patients received chemotherapy (37%); common palliative therapies included radiotherapy, radionuclide therapy, bisphosphonates, and opioids.

Conclusions:

• CRPC is associated with a poor prognosis and a median survival of 9-13 months for metastatic cases.
• Progression to CRPC leads to a decline in quality of life, with limited therapeutic options available.
• Standardized definitions and methodologies are crucial for future well-designed epidemiological studies of CRPC.